Indo-US healthcare cooperation is in the limelight as India approves 2 more COVID vaccines. India News – Times of India

WASHINGTON: Indo-US collaboration in the health sector is in the news as the Central Drugs Authority this week approved two more COVID vaccines – Corbevax and Kovovax – and the antiviral drug mollupiravir for use in India.
India’s Ambassador to the US Taranjit Singh Sandhu in a tweet called it a model of Indo-US health cooperation.
“What India-United States Models of Health Cooperation Can Achieve for the Global Good!” Sandhu said.

Indian companies working with kids of texasis, Baylor College of Medicine’s National School of Tropical Medicine; Dr. Peter Hotez, Professor And Dean co-director of the National School of Tropical Medicine and Texas Children’s Hospital Center for Vaccine Development at Baylor; Novavax; Merck and Ridgeback Bio, the Indian diplomat tweeted.
During his visit to Houston in October, Sandhu had met Professor Hotez and discussed the issue.
In June of this year, the ambassador visited the Novavax facility in Maryland. He also spoke to Sanisure CEO Thomas Hook.
Sanisure supplies components for the SII – Novavax collaboration. These have been part of an ongoing outreach that Ambassador has done with vaccine manufacturers and pharma companies.
Corbevax, a protein sub-unit COVID-19 vaccine, the technology of which was designed and engineered in collaboration with Texas Children’s Hospital and Baylor College of Medicine, has received emergency use authorization (EUA) from the Drugs Controller General of India (DCGI). Approval has been received. Texas Children’s Hospital said in a statement that the vaccine is being launched in India along with other ineligible countries.
“This announcement is an important first step in vaccinating the world and stopping the pandemic. Our vaccine technology provides a way to address a humanitarian crisis, namely the vulnerability of low- and middle-income countries against the delta variant. Have to do it,” said Hotez.
“Widespread and global vaccination with our Texas Children’s-Boiler-BE vaccine will also prevent the emergence of new variants. We previously missed that opportunity for alpha and delta variants. Now we have a chance to stop a new global wave.” Which can happen later,” he said.
Touted as “the world’s COVID-19 vaccine”, it uses a traditional recombinant protein-based technology to make its production widely accessible to vaccinate the global population on a large scale, the statement said. Will give
Corbevax was found to be safe, well tolerated and immunogenic after completing two Phase III clinical trials involving over 3,000 subjects. It demonstrated a better immune response than the Covishield vaccine when assessed for geometric mean titers (GMT) of neutralizing antibodies (NABs) against the parental–Wuhan strain and the globally dominant delta variant.
Corbevax vaccination also generates significant Th1 skewed cellular immune responses